Publication details

Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients

Authors

CORTHALS SL. KUIPER R. JOHNSON DC. SONNEVELD P. HÁJEK Roman VAN DER HOLT B. MAGRANGEAS F. GOLDSCHMIDT H. MORGAN GJ. AVET-LOISEAU H.

Year of publication 2011
Type Article in Periodical
Magazine / Source Haematologica/the hematology journal
MU Faculty or unit

Faculty of Medicine

Citation
Doi http://dx.doi.org/10.3324/haematol.2011.041434
Field Oncology and hematology
Keywords bortezomib; peripheral neuropathy; risk; single nucleotide polymorphism
Description Bortezomib induced peripheral neuropathy is a dose-limiting side effect and a major concern in the treatment of multiple myeloma. To identify genetic risk factors associated with the development of this side effect in bortezomib treated multiple myeloma patients, a pharmacogenetic association study was performed using a discovery set (IFM 2005-01; n=238) and a validation set (HOVON65/GMMG-HD4 and a Czech dataset; n=231). After multiplicity correction, none of the 2,149 single nucleotide polymorphisms tested revealed any significant association with bortezomib induced peripheral neuropathy. However, 56 single nucleotide polymorphisms demonstrated an association with bortezomib induced peripheral neuropathy with pointwise, uncorrected significance. Pathway analysis of these polymorphisms demonstrated involvement of neurological disease (FDR <20%). Also a clear enrichment of major bortezomib metabolizing genes was found. Univariate evaluation of these 56 polymorphisms in the validation set demonstrated one single nucleotide polymorphism with pointwise significance: rs619824 in CYP17A1. (IFM 2005-01 clinicaltrials.gov identifier: NCT00200681; HOVON-65/GMMG-HD4 isrctn.org identifier: ISRCTN64455289)
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info